Free Trial
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

Crinetics Pharmaceuticals logo
$30.10 +0.60 (+2.05%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Key Stats

Today's Range
$29.30
$30.64
50-Day Range
$25.56
$35.94
52-Week Range
$24.10
$62.53
Volume
627,107 shs
Average Volume
1.01 million shs
Market Capitalization
$2.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.56
Consensus Rating
Moderate Buy

Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

CRNX MarketRank™: 

Crinetics Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 239th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Crinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Crinetics Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Crinetics Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.73) to ($4.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Crinetics Pharmaceuticals is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Crinetics Pharmaceuticals is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Crinetics Pharmaceuticals has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Crinetics Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.51% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Crinetics Pharmaceuticals has recently increased by 2.18%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Crinetics Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Crinetics Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.51% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Crinetics Pharmaceuticals has recently increased by 2.18%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Crinetics Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Crinetics Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    2 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $923,913.00 in company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Crinetics Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Crinetics Pharmaceuticals' insider trading history.
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
See More Headlines

CRNX Stock Analysis - Frequently Asked Questions

Crinetics Pharmaceuticals' stock was trading at $51.13 at the start of the year. Since then, CRNX stock has decreased by 41.4% and is now trading at $29.9550.
View the best growth stocks for 2025 here
.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by $0.05. The business's revenue for the quarter was down 43.6% compared to the same quarter last year.
Read the conference call transcript
.

Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Top institutional shareholders of Crinetics Pharmaceuticals include Vanguard Group Inc. (9.95%), Wellington Management Group LLP (7.36%), Driehaus Capital Management LLC (6.66%) and Price T Rowe Associates Inc. MD (5.46%). Insiders that own company stock include Richard Scott Struthers, Marc Wilson, Jeff E Knight, Dana Pizzuti, Stephen F Betz, Alan Seth Krasner, James Hassard, Matthew K Fust, Stephanie Okey and Coelho Rogerio Vivaldi.
View institutional ownership trends
.

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/08/2025
Today
5/28/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.56
High Stock Price Target
$97.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+152.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$214.53 million
Pretax Margin
-26,298.27%

Debt

Sales & Book Value

Annual Sales
$760,000.00
Price / Cash Flow
N/A
Book Value
$8.07 per share
Price / Book
3.66

Miscellaneous

Free Float
87,174,000
Market Cap
$2.76 billion
Optionable
Optionable
Beta
0.31
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CRNX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners